Published in Women's Health Weekly, July 8th, 2004
Objective response or stable disease (lasting 8-16 weeks) were reported in 46% of women (scheduled interim analysis, first 41 patients on study) with heavily pretreated advanced metastatic breast cancer whose disease had previously progressed on trastuzumab (Herceptin) containing regimens (including chemotherapy, hormones, etc.), according to interim results.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly